title: Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
abstract: Thirty patients suffering from essential hypertension were treated successively with placebo, hydralazine alone, and pindolol (Visken) combined with hydralazine. Hydralazine caused a statistically significant reduction in blood pressure and an increase in pulse rate as compared with the placebo: palpitations were an irritating side-effect. The combination of hydralazine and pindolol resulted in an additional fall in blood pressure (p less than 0.001) and the pulse rate decreased (2 p less than 0.001). The combined treatment also had a favourable effect on palpitations and angina pectoris.
mesh_terms: D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage* / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000008:administration & dosage* / Q000627:therapeutic use; D010919:Placebos
chemical_list: D010919:Placebos; D006830:Hydralazine; D010869:Pindolol